The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE).
The U.S. Food and Drug Administration has approved GlaxoSmithKline s 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy.
A child's health care provider can determine if at-home administration is appropriate, and if so, the patient's caregiver can administer the medicine at home.